New drug combo tested in kids with tough cancers
NCT ID NCT01282697
Summary
This study tested a new combination of two existing drugs, rapamycin and irinotecan, in children and young adults whose solid tumors did not respond to standard treatments. The main goal was to find the highest dose of this combination that could be given safely. Researchers also wanted to see how the drugs behaved in the body and if they could help control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS IN CHILDREN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU La Timone
Marseille, 13005, France
-
CHU Mère-Enfants
Nantes, 44093, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital des Enfants
Toulouse, 31059, France
-
Hôpital des Enfants - Groupe Hospitalier Pellegrin
Bordeaux, 33076, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Hémato-Oncologie Pédiatrique (IHOP)
Lyon, 67008, France
Conditions
Explore the condition pages connected to this study.